GPT and hepatocellular carcinoma: With regard to the safety profile of CSM-TACE, a previous study illustrated that liver function indices (namely, TP, TBIL, ALT, and AST) were similar among hepatocellular carcinoma patients before and after 1–3 months of CSM-TACE; meanwhile, the main adverse events included pain, fever, nausea, and vomiting, which were all manageable and tolerable (30).